Replimune Group Inc

REPL is in a Stage 2 advancing corrective reset within a long-term downtrend. Medium-term bias remains bullish on the Stage 2 higher-high/higher-low structure, but the recent rejection below the 9/21 EMAs makes short-term timing unfavorable. Under the Speculative strategy, execution is deferred and focused on pullbacks into the rising 50-day EMA and prior support zone for selective entry rather than chasing current weakness.

• ↑Q4 cash of $483.8M (+15% YoY) provides runway for RP1 launch
• ↑Up to 80% of ~13k US PD-1 nonresponders eligible for RP1 annually
• ↓Fiscal net loss $247.3M highlights weak profitability and margin conversion